Akcea Therapeutics secures exclusive license

Akcea Therapeutics Inc. (Nasdaq: AKCA) secured an exclusive, worldwide license from Ionis Pharmaceuticals Inc. (Nasdaq: IONS) to commercialize inotersen and AKCEA-TTR-L. Shares of Akcea Therapeutics leaped $7.80 to close at $28.14 while Ionis stock dropped $1.39 to close at $52.18.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.